Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTH Replacement in Hypoparathyroidism
NCT00395538Phase 3Terminated
- Sponsor
- National Institute of Dental and Craniofacial Research
- Start
- Oct 2006
- Primary completion
- Sep 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of ZT-034 in hypoparathyroidism and DiGeorge syndrome (DGS), sponsored by National Institute of Dental and Craniofacial Research. Primary endpoint: Cancellous Bone Volume at 4 years. Started Oct 2006; status: terminated.
02
Drugs
ZT-034
03
Conditions
hypoparathyroidismDiGeorge syndrome (DGS)
Beyond the preview
Go deeper on NCT00395538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00395538.